Skip to main content
. 2010 Jan 19;12(5):374–379. doi: 10.1111/j.1751-7176.2009.00259.x

Table I.

 Baseline Treatments According to the Presence of the Metabolic Syndrome (MS)

Treatments Overall (n=642; 100%) MS (n=171; 26.7%) No MS (n=471; 73.3%) P Value
Antiplatelets, % 97.2   96.4 97.5 Not significant
Anticoagulants, %  9.0   11.2  8.3 <.05
β‐Blockers, % 74.5   72.6 75.1 Not significant
Angiotensin‐renin system inhibitor, % 51.7   45.3 54.1 <.05
Lipid‐lowering drugs, % 99.7 100 99.6 Not significant
Antidiabetics, % 11.7   21.7  7.4 <.05